Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
暂无分享,去创建一个
J. Rockstroh | J. Trebicka | C. Boesecke | J. Wasmuth | K. van Bremen | J. Bischoff | W. Gu | L. Dold | C. Schwarze‐Zander
[1] H. Stellbrink,et al. Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Muriel,et al. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study , 2021, Journal of the International AIDS Society.
[3] H. Günthard,et al. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV , 2021, Annals of Internal Medicine.
[4] G. Maartens,et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. , 2020, The lancet. HIV.
[5] H. Jessen,et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial , 2020, The Lancet.
[6] T. Cotter,et al. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .
[7] J. Milic,et al. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus , 2020, Clinical Infectious Diseases.
[8] Richard D Moore,et al. Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada , 2020, Journal of the International AIDS Society.
[9] K. White,et al. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight , 2020, PloS one.
[10] F. Villarroya,et al. Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV , 2020, International Journal of Obesity.
[11] V. Wong,et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study , 2020, The lancet. Gastroenterology & hepatology.
[12] J. Rockstroh,et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials , 2019, Journal of acquired immune deficiency syndromes.
[13] C. Yanavich,et al. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono‐infection under long‐term combined antiretroviral therapy , 2018, Journal of the International AIDS Society.
[14] J. Bogner,et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017 , 2018, Infection.
[15] R. D. De Boni,et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors , 2018, The Journal of antimicrobial chemotherapy.
[16] D. Glidden,et al. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] J. Rockstroh,et al. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis , 2018, Medicine.
[18] S. Bhagani,et al. Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies. , 2018, Journal of acquired immune deficiency syndromes.
[19] G. Baffy. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? , 2018, Advances in experimental medicine and biology.
[20] Sally S Bebawy,et al. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens , 2017, Journal of acquired immune deficiency syndromes.
[21] P. Tien,et al. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults , 2017, AIDS.
[22] M. Thursz,et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection , 2017, AIDS.
[23] P. Brouqui,et al. Dolutegravir and weight gain: an unexpected bothering side effect? , 2017, AIDS.
[24] J. Rockstroh. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV , 2017, Current HIV/AIDS Reports.
[25] J. Routy,et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients , 2016, AIDS.
[26] M. Charlton,et al. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health , 2016, Hepatology.
[27] J. Rockstroh,et al. Liver Fibrosis in HIV Patients Receiving a Modern cART , 2015, Medicine.
[28] R. Weber,et al. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy , 2015, PloS one.
[29] D. Leaf,et al. Weight change after antiretroviral therapy and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] G. Sebastiani,et al. Incidence and Predictors of Hepatic Steatosis and Fibrosis by Serum Biomarkers in a Large Cohort of Human Immunodeficiency Virus Mono-Infected Patients , 2015, Open forum infectious diseases.
[31] J. Rockstroh,et al. Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play? , 2014, Current opinion in HIV and AIDS.
[32] C. Tural,et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients , 2014, AIDS.
[33] V. de Lédinghen,et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. , 2014, Journal of hepatology.
[34] M. Budoff,et al. Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study , 2014, The American Journal of Gastroenterology.
[35] R. DeFronzo,et al. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.
[36] S. Chow,et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. , 2013, AIDS research and human retroviruses.
[37] R. Sterling,et al. Hepatic Steatosis in Human Immunodeficiency Virus: A Prospective Study in Patients Without Viral Hepatitis, Diabetes, or Alcohol Abuse , 2013, Journal of clinical gastroenterology.
[38] Laurent Castera,et al. Noninvasive methods to assess liver disease in patients with hepatitis B or C. , 2012, Gastroenterology.
[39] Giorgio Saracco,et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.
[40] G. Ligabue,et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.